{"filing":{"accession_number":"0001171843-26-005981","cik":"0001729214","ticker":"XRTX","company_name":"XORTX Therapeutics Inc.","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"f6k_091026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1729214/000117184326005981/f6k_091026.htm"},"events":[{"id":32679,"run_id":30040,"accession_number":"0001171843-26-005981","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"XORTX announces initiation of clinical and commercial manufacturing of XORLO™ (oxypurinol) to support the XRX-OXY-102 clinical study and future FDA marketing approval. This is a material operational milestone—the company has begun GMP drug substance production and is working with contract manufacturers on commercial-scale tablet manufacturing. While not a discrete M\u0026A, financing, or governance event, this manufacturing progress is a key step toward regulatory approval of the company's lead XRx-026 program for gout treatment and would affect a reasonable investor's assessment of development progress and timeline to potential commercialization.","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35911,"accession_number":"0001171843-26-005981","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"XORTX announces initiation of clinical and commercial manufacturing of XORLO™ (oxypurinol) to support the XRX-OXY-102 clinical study and future FDA marketing approval. This is a material operational milestone—the company has begun GMP drug substance production and is working with contract manufacturers on commercial-scale tablet manufacturing. While not a discrete M\u0026A, financing, or governance event, this manufacturing progress is a key step toward regulatory approval of the company's lead XRx-026 program for gout treatment and would affect a reasonable investor's assessment of development progress and timeline to potential commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:20:58.981478+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35911,"accession_number":"0001171843-26-005981","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"XORTX announces initiation of clinical and commercial manufacturing of XORLO™ (oxypurinol) to support the XRX-OXY-102 clinical study and future FDA marketing approval. This is a material operational milestone—the company has begun GMP drug substance production and is working with contract manufacturers on commercial-scale tablet manufacturing. While not a discrete M\u0026A, financing, or governance event, this manufacturing progress is a key step toward regulatory approval of the company's lead XRx-026 program for gout treatment and would affect a reasonable investor's assessment of development progress and timeline to potential commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:20:58.981478+00:00","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-09-10"}]}